NCT05853458 - Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 28, 2023

Primary Completion Date

June 1, 2026

Study Completion Date

January 27, 2027

Conditions

Polycythemia Vera

Interventions

DRUG

Hydroxyurea

Hydroxyurea is commercially available in Germany and will be prescribed based on clinical judgment

Trial Locations (26)

10407

Novartis Investigative Site, Berlin

23563

Novartis Investigative Site, Lübeck

24105

Novartis Investigative Site, Kiel

26655

Novartis Investigative Site, Westerstede

30161

Novartis Investigative Site, Hanover

33332

Novartis Investigative Site, Gütersloh

42551

Novartis Investigative Site, Velbert

44309

Novartis Investigative Site, Dortmund

47441

Novartis Investigative Site, Moers

49808

Novartis Investigative Site, Lingen Ems

50671

Novartis Investigative Site, Cologne

50674

Novartis Investigative Site, Cologne

52064

Novartis Investigative Site, Aachen

52146

Novartis Investigative Site, Würselen

53113

Novartis Investigative Site, Bonn

63225

Novartis Investigative Site, Langen

66113

Novartis Investigative Site, Saarbrücken

69115

Novartis Investigative Site, Heidelberg

73557

Novartis Investigative Site, Mutlangen

85435

Novartis Investigative Site, Erding

86609

Novartis Investigative Site, Donauwörth

94315

Novartis Investigative Site, Straubing

96317

Novartis Investigative Site, Kronach

06217

Novartis Investigative Site, Merseburg

01307

Novartis Investigative Site, Dresden

04683

Novartis Investigative Site, Naunhof